Docality.com Logo
 
Dr. Nita  Amornsiripanitch  Md image

Dr. Nita Amornsiripanitch Md

1633 N Capitol Ave Suite 640
Indianapolis IN 46202
317 620-0838
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 11016030A
NPI: 1063791887
Taxonomy Codes:
2085R0202X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Complement factor H autoantibodies are associated with early stage NSCLC. - Clinical cancer research : an official journal of the American Association for Cancer Research
To discover diagnostic biomarkers associated with early-stage non-small cell lung cancer (NSCLC), we searched for autoantibodies preferentially present in stage I patients compared with patients with advanced-stage disease. Here we describe an autoantibody against complement factor H (CFH) and this autoantibody's association with early-stage NSCLC.Immunoblots were used to detect autoantibodies in the sera of stage I NSCLC patients. An autoantibody recognizing a 150 kDa protein was discovered, and the protein was identified by mass spectrometry. The association of the autoantibody with early-stage disease was suggested by the results of immunoblot analysis with sera from 28 stage I patients and 28 stage III/IV patients. This association was confirmed by protein microarray of sera from 125 NSCLC patients of all stages as well as 125 controls matched by age, gender, and smoking history.The immunoreactive protein was identified as CFH. By immunoblot analysis, anti-CFH autoantibody was found in 50% of stage I NSCLC patients and 11% of late-stage NSCLC patients (P = 0.003). By protein microarray analysis, patients with stage I NSCLC had a significantly higher incidence of anti-CFH antibody than those with late-stage NSCLC (P = 0.0051). The percentage of sera with a positive level of CFH autoantibody was 30.4% in stage I, 21.1% in stage II, 12.5% in stage III, 7.4% in stage IV, and 8.0% in the control group.These findings suggest that in patients with NSCLC, CFH autoantibody is a molecular marker associated with early-stage disease.(c) 2010 AACR.
A genomic approach to identify regulatory nodes in the transcriptional network of systemic acquired resistance in plants. - PLoS pathogens
Many biological processes are controlled by intricate networks of transcriptional regulators. With the development of microarray technology, transcriptional changes can be examined at the whole-genome level. However, such analysis often lacks information on the hierarchical relationship between components of a given system. Systemic acquired resistance (SAR) is an inducible plant defense response involving a cascade of transcriptional events induced by salicylic acid through the transcription cofactor NPR1. To identify additional regulatory nodes in the SAR network, we performed microarray analysis on Arabidopsis plants expressing the NPR1-GR (glucocorticoid receptor) fusion protein. Since nuclear translocation of NPR1-GR requires dexamethasone, we were able to control NPR1-dependent transcription and identify direct transcriptional targets of NPR1. We show that NPR1 directly upregulates the expression of eight WRKY transcription factor genes. This large family of 74 transcription factors has been implicated in various defense responses, but no specific WRKY factor has been placed in the SAR network. Identification of NPR1-regulated WRKY factors allowed us to perform in-depth genetic analysis on a small number of WRKY factors and test well-defined phenotypes of single and double mutants associated with NPR1. Among these WRKY factors we found both positive and negative regulators of SAR. This genomics-directed approach unambiguously positioned five WRKY factors in the complex transcriptional regulatory network of SAR. Our work not only discovered new transcription regulatory components in the signaling network of SAR but also demonstrated that functional studies of large gene families have to take into consideration sequence similarity as well as the expression patterns of the candidates.

Map & Directions

1633 N Capitol Ave Suite 640 Indianapolis, IN 46202
View Directions In Google Maps

Nearby Doctors

702 Barnhill Dr Riley Hospital
Indianapolis, IN 46202
317 744-4034
1801 N Senate Blvd Ste 535
Indianapolis, IN 46202
317 631-1950
535 Barnhill Dr.
Indianapolis, IN 46202
317 744-4622
1801 N Senate Blvd Suite 535
Indianapolis, IN 46202
317 631-1950
1801 N Senate Blvd Suite 355
Indianapolis, IN 46202
317 248-8420
545 Barnhill Dr Eh 435
Indianapolis, IN 46202
317 448-8660
550 University Blvd Uh 1501
Indianapolis, IN 46202
317 481-1310
541 Clinical Drive, Room 370 Indiana University School Of Medicine
Indianapolis, IN 46202
314 165-5305